HIV/AIDS Topics Small Molecule Compound 5HN Flushes Out Latent HIV in Reservoir CD4 T-cells
- Details
- Category: Search for a Cure
- Published on Friday, 16 October 2009 14:13
- Written by Liz Highleyman
A newly identified compound known as 5HN appears to "flush out" HIV from latent T-cells, potentially making the virus susceptible to eradication from the body, according to research published in the October 1, 2009 advance online edition of Journal of Clinical Investigation.
Meta-Analysis of Truvada vs Epzicom Backbones Used with Boosted Protease Inhibitors for First-line Antiretroviral Therapy
- Details
- Category: HIV Treatment
- Published on Friday, 09 October 2009 14:13
- Written by HIVandHepatitis.com
First-line antiretroviral therapy (ART) that includes a nucleoside/nucleotide backbone of tenofovir/emtricitabine (the drugs in the Truvada coformulation) was more effective than regimens containing abacavir/lamivudine (the drugs in the Epzicom coformulation) for HIV patients with high pre-treatment viral load, according to a meta-analysis published in the October 2009 issue of HIV Medicine.
ICAAC 2009: Tobacco and Marijuana May Significantly Lower Atazanavir (Reyataz) Blood Levels
- Details
- Category: HIV Treatment
- Published on Tuesday, 15 September 2009 13:48
- Written by Liz Highleyman
Use of tobacco and marijuana reduced trough (lowest level between doses) blood concentrations of the protease inhibitor atazanavir (Reyataz), although the effects of alcohol, cocaine, and opiates such as heroin did not reach statistical significance, according to a poster presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2009) this week in San Francisco.
ICAAC 2009: Raltegravir (Isentress) plus Atazanavir (Reyataz) Maintenance Therapy Appears Safe and Effective in Small Study
- Details
- Category: HIV Treatment
- Published on Friday, 02 October 2009 13:48
- Written by Liz Highleyman
A dual maintenance regimen consisting of the recently approved integrase inhibitor raltegravir (Isentress) plus the protease inhibitor atazanavir (Reyataz) was well tolerated and kept viral load below 50 copies/mL in more than 80% of patients with no prior history of treatment failure, according to a study presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2009) last month in San Francisco.
Some Prisoners Can Achieve Good Hepatitis C Treatment Outcomes, but Response Rates May be Lower than those of Non-inmates
- Details
- Category: HIV Treatment
- Published on Friday, 11 September 2009 14:01
- Written by HIVandHepatitis.com
Some prisoners with chronic hepatitis C virus (HCV) infection -- especially genotypes 2 or 3 -- can achieve sustained response using pegylated interferon plus ribavirin, but the likelihood of responding is lower than it is for patients in the outside community, according to a study in the August 2009 Journal of Clinical Gastroenterology.
ICAAC 2009: Nevirapine (Viramune) and Boosted Atazanavir (Reyataz) Produce Comparable Early Virological and Immunological Response
- Details
- Category: HIV Treatment
- Published on Tuesday, 22 September 2009 13:48
- Written by Ronald Baker
Early virological response has been proposed as a marker of efficacy of antiretroviral therapy (ART). In the ARTEN trial, nevirapine (Viramune) showed similar efficacy to ritonavir-boosted atazanavir (Reyataz), but with a more favorable lipid profile after 48 weeks. Results from a sub-analysis of the ARTEN trial looking at early virological and immunological response were presented last week at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2009) in San Francisco last week.
Avexa Closes Trial of Experimental NRTI Apricitabine, Will Evaluate 24-week Data
- Details
- Category: Experimental HIV Drugs
- Published on Wednesday, 09 September 2009 14:13
- Written by Avexa
Avexa recently announced that it will close a Phase 3 study of its investigational nucleoside reverse transcriptase inhibitor (NRTI) candidate apricitabine, and will analyze 24-week data ahead of schedule. The company did not specify why the study is being halted at this time. Results from the pending analysis are expected early next year.
More Articles...
- HIV-HBV Coinfected Patients Respond to Antiretroviral Therapy as well as HIV Monoinfected, but Have a Higher Risk of Non-AIDS Death
- IAS 2009: ARIES Trial Shows Unboosted Atazanavir (Reyataz) Maintains Viral Suppression as well as Boosted Drug
- Shionogi-GlaxoSmithKline Pharmaceuticals Will Revise Inclusion Criteria for a Clinical Study of the Experimental Integrase Inhibitor S/GSK1349572 To Incorporate Concerns of HIV Treatment Advocates
- STARTMRK Trial Shows Raltegravir (Isentress) Works as Well as Efavirenz (Sustiva) in Treatment-naive HIV Patients
- IAS 2009: Can People in Low-income Countries Benefit from Antiretroviral Therapy without Routine Laboratory Monitoring?
Web Design and Development by